OrbiMed’s Avalo Therapeutics AVTX Stock Holding History

OrbiMed’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-475,165	Closed	-$7.09M	–	134
2026 Q1	$7.09M	Sell	475,165 -712,135	-60%	-$11.1M	0.14%	85
2025 Q4	$21.6M	Sell	1,187,300 -162,000	-12%	-$2.73M	0.44%	57
2025 Q3	$17.1M	Buy	1,349,300 +382,300	+40%	+$3.29M	0.4%	57
2025 Q2	$4.83M	Hold	967,000	–	–	0.12%	78
2025 Q1	$7.75M	Hold	967,000	–	–	0.18%	69
2024 Q4	$7.18M	Hold	967,000	–	–	0.15%	76
2024 Q3	$9.19M	Buy	+967,000	New	+$9.97M	0.17%	80

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

OrbiMed's AVTX Position: Q2 2026 in Review

OrbiMed sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 475,165 shares — an estimated $7.09M sold.

OrbiMed first reported a position in AVTX in Q3 2024 and held it in 7 quarters. The position peaked at $21.6M in Q4 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

OrbiMed reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
OrbiMed sold 475,165 Avalo Therapeutics shares in Q2 2026, an estimated $7.09M.
OrbiMed first reported a position in Avalo Therapeutics in Q3 2024 and held it in 7 quarters.
OrbiMed's Avalo Therapeutics position peaked at $21.6M in Q4 2025.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.